Olema Pharmaceuticals, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Olema completed enrollment in pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in ER+/HER2- metastatic breast cancer, with top-line data expected Q1 2027. Company ended Q2 2026 with $461.1M cash (down $44.4M from $505.4M at year-end 2025). Q2 net loss was $63.2M vs. $43.8M YoY; R&D expenses rose to $57.8M from $43.9M; G&A doubled to $9.4M from $4.0M. Bayer collaboration announced to evaluate OP-3136 plus darolutamide in prostate cancer.
Why this rating
Phase 3 enrollment completion and near-term data catalyst are meaningful for ~$243M biotech; cash burn ($44M/quarter) and $461M runway manageable but limited; Bayer partnership expands pipeline validation
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.